Track topics on Twitter Track topics that are important to you
Can what you eat alter the progression of amyotrophic lateral sclerosis (ALS)? We propose that the answer may be yes. Mitochondrial dysfunction may play a pivotal role in the death of motor neurons in ALS. Ketones, generated from ketogenic diets, can overcome certain types of mitochondrial dysfunction and in doing so, help restore the motor neuron to better health and thereby slow or stop the disease progression. The primary aim of our study is to prove that ketogenic diets are safe and tolerable in patients with ALS so that larger studies to test this hypothesis can be safely performed.
The cause of amyotrophic lateral sclerosis is unknown. There is growing evidence implicating mitochondrial dysfunction as being an integral part of the process that ultimately results in the death of the motor neuron. Studies from the G93A transgenic mouse model of ALS show abnormal mitochondrial structure, intramitochondrial inclusions, possible mitochondrial sites of direct interaction with the mutant SOD1 molecule, and disruption of the energy generating function of the mitochondrion, particularly complex I, the NADH dehydrogenase complex. In vitro and preliminary evidence from G93A mice suggest that ketones, particularly D beta hydroxybutyrate (DßHB) are able to stimulate other components of the mitochondrial membrane complexes (2,3,4 and cytochrome c) when complex 1 is blocked, essentially bypassing the dysfunctional complex I and providing continued mitochondrial energy supply. DßHB is one of the main products formed during ketosis, the metabolic state resulting from an effective ketogenic diet. When G93A transgenic mice are maintained on a ketogenic diet, the ketotic animals live longer, have better motor performance, and have significantly larger diameter neurons remaining in the anterior horn region of the spinal cord compared to disease controls. Interestingly, G93 mice seemed to produce more ketones compared to control animals fed the same high fat, low carbohydrate diet, suggesting the possibility of an inherent defect in metabolizing fats and protein in the setting of hypoglycemia.
Ketogenic diets have been used for decades to treat intractable seizures. The mechanism conferring anticonvulsant activity is uncertain, but one possible mechanism may be related to hyperpolarization resulting from increased levels of ATP. Ketogenic diets have never been used in patients with ALS. Therefore the specific aims of our study are the following: 1. To determine if gastrostomy-fed ALS patients adhering to the 4:1 ketogenic diet (ratio of grams of fat to grams of protein plus carbohydrate) is safe and tolerable. We will determine safety and tolerance by measuring incidence and severity of adverse effects as well as careful monitoring of weight. 2. To evaluate changes in strength, fatigue and cognitive function while strictly adhering to the ketogenic diet. 3. To evaluate the changes in the percentage of body fat during the course of the study to determine the metabolic impact of the ketogenic diet. If safety and tolerability are established, further studies to determine efficacy of the ketogenic diet in patients with ALS will be planned.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Amyotrophic Lateral Sclerosis
The Robert Packard Center for ALS Research at Johns Hopkins
Weill Medical College of Cornell University
Published on BioPortfolio: 2014-08-27T03:17:11-0400
This research is being done to see if the ketogenic diet (which is high in fat and low in carbohydrates) is safe and tolerable in amyotrophic lateral sclerosis (ALS) patients who are fed t...
The goal of this study is to investigate the safety and tolerability of allogeneic Wharton's jelly-derived mesenchymal stem cells administration in the individuals with diagnosed amyotroph...
OBJECTIVES: I. Determine specific clinical features, molecular abnormalities, and laboratory-based biological markers of free radical stress that are associated with amyotrophic lateral...
The purpose of this study is to investigate the efficacy and confirm the safety of E0302 in patients with Amyotrophic Lateral Sclerosis (ALS) by assessing changes in scores of survival rat...
The purpose of this study is to evaluate the safety and pharmacokinetics of GDC-0134 in patients with Amyotrophic Lateral Sclerosis (ALS).
There is an increasing clinical research focus on neuroprotective agents in amyotrophic lateral sclerosis (ALS). However, it is unclear how generalisable clinical study trial results are between diffe...
Knowledge about the metabolic states of patients with amyotrophic lateral sclerosis (ALS) may provide a therapeutic approach.
Amyotrophic lateral sclerosis (ALS) affects persons of all races, and there continues to be a need for effective therapies to treat the disease.
Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis.
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
There continues to be a need for new therapies to treat ALS.
A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
A superoxide dismutase (SOD1) that requires copper and zinc ions for its activity to destroy SUPEROXIDE FREE RADICALS within the CYTOPLASM. Mutations in the SOD1 gene are associated with AMYOTROPHIC LATERAL SCLEROSIS-1.
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
A Poly(A) RNA-binding protein that negatively regulates EGFR ENDOCYTOSIS. An increased risk for developing AMYOTROPHIC LATERAL SCLEROSIS 13 is observed in patients who have more than 23 CAG repeats in the ATXN2 gene coding sequence. Larger CAG expansions in the ATXN2 gene occur in SPINOCEREBELLAR ATAXIA 2 patients.
Diseases characterized by the presence of abnormally phosphorylated, ubiquitinated, and cleaved DNA-binding protein TDP-43 in affected brain and spinal cord. Inclusions of the pathologic protein in neurons and glia, without the presence of AMYLOID, is the major feature of these conditions, thus making these proteinopathies distinct from most other neurogenerative disorders in which protein misfolding leads to brain amyloidosis. Both frontotemporal lobar degeneration and AMYOTROPHIC LATERAL SCLEROSIS exhibit this common method of pathogenesis and thus they may represent two extremes of a continuous clinicopathological spectrum of one disease.
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...